

**Children's Hospital Of Eastern Ontario**

**MASTER FORMULA SHEET – NON-STERILE MANUFACTURING**

**PRODUCT:** HYDROCHLOROTHIAZIDE 5 mg/mL SUSPENSION

**Date Prepared:** \_\_\_\_\_

**FINAL PRODUCT CHECKED BY:** \_\_\_\_\_

**EXPIRY DATE:** \_\_\_\_\_

INGREDIENT	MANUFACTURER	LOT #	MAN. EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	MFG BY	CHK BY
Hydrochlorothiazide 50 mg tablet				5 tablets			
Ora-Blend®	Paddock			qs to 50 mL			

**EQUIPMENT**

- Mortar and pestle
- Graduated cylinder

**MANUFACTURING DIRECTIONS**

1. Crush tablets to make a fine powder in a mortar.
2. Levigate powder with a small amount of the vehicle to make a fine paste.
3. Continue to add vehicle until product is liquid enough to transfer to a graduated cylinder.
4. Rinse mortar several times with vehicle and add to product in graduated cylinder.
5. QS to final volume with vehicle.
6. Dispense in amber plastic bottles.

**FINAL APPEARANCE**

Opaque white Suspension

**SAMPLE LABEL**

**HYDROCHLOROTHIAZIDE 5 mg/mL Suspension**

Shake well. Room Temperature/Refrigerate

Date Prepared: \_\_\_\_\_ Date Expired: \_\_\_\_\_

**STABILITY**

60 days refrigerated or at room temperature.

**REFERENCE(S)**

- Nahata MC, Hipple TF, Pediatric Drug Formulations, 4<sup>th</sup> ed. 2000, pp 115
- Allen LV, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. AJHP 1996, 53: 2304-9

***Master Sheet Revision Dates: 11 Nov 06; Feb 2019***

The non-sterile manufacturing formulas are provided for informational purposes for qualified health care professionals. The hospital will not assume responsibility for the continued currency of the information, any errors or omissions, and/or any consequences arising from the use of the information outside of CHEO.